Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 58,600 shares, a decline of 9.6% from the July 15th total of 64,800 shares. Approximately 6.0% of the shares of the stock are sold short. Based on an average daily volume of 19,800 shares, the short-interest ratio is presently 3.0 days.
Institutional Trading of Avalo Therapeutics
A hedge fund recently bought a new stake in Avalo Therapeutics stock. Affinity Asset Advisors LLC acquired a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the company’s stock, valued at approximately $218,000. Affinity Asset Advisors LLC owned approximately 0.97% of Avalo Therapeutics as of its most recent SEC filing. 87.06% of the stock is owned by hedge funds and other institutional investors.
Avalo Therapeutics Stock Down 2.5 %
NASDAQ AVTX traded down $0.23 during mid-day trading on Friday, reaching $9.07. 10,815 shares of the stock were exchanged, compared to its average volume of 286,616. The business’s fifty day simple moving average is $11.70 and its 200 day simple moving average is $10.34. Avalo Therapeutics has a 1-year low of $3.95 and a 1-year high of $71.04.
About Avalo Therapeutics
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
See Also
- Five stocks we like better than Avalo Therapeutics
- Investing In Preferred Stock vs. Common Stock
- This Small Cap Wealth Management Stock Could Provide Big Returns
- The Most Important Warren Buffett Stock for Investors: His Own
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Invest in Biotech Stocks
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.